C.M. Bidwell & Associates’s DexCom DXCM Stock Holding History

C.M. Bidwell & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,946	Closed	-$334K	–	519
2024 Q2	$334K	Sell	2,946 -7	-0.2%	-$885	0.22%	78
2024 Q1	$410K	Sell	2,953 -6	-0.2%	-$754	0.28%	67
2023 Q4	$367K	Buy	2,959 +1,155	+64%	+$118K	0.27%	72
2023 Q3	$168K	Buy	+1,804	New	+$203K	0.13%	136
2019 Q2	–	Sell	-12,200	Closed	-$363K	–	408
2019 Q1	$363K	Buy	12,200 +10,620	+672%	+$373K	0.36%	85
2018 Q4	$47K	Hold	1,580	–	–	0.05%	246
2018 Q3	$57K	Hold	1,580	–	–	0.05%	223
2018 Q2	$38K	Hold	1,580	–	–	0.04%	263
2018 Q1	$29K	Hold	1,580	–	–	0.03%	269
2017 Q4	$23K	Buy	+1,580	New	+$20.5K	0.02%	284
2015 Q2	–	Sell	-11,100	Closed	-$173K	–	233
2015 Q1	$173K	Buy	+11,100	New	+$168K	0.04%	175

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

C.M. Bidwell & Associates's DXCM Position: Q3 2024 in Review

C.M. Bidwell & Associates sold out of DexCom (DXCM) in Q3 2024, closing a stake of 2,946 shares — an estimated $334K sold.

C.M. Bidwell & Associates first reported a position in DXCM in Q1 2015 and held it in 11 quarters. The position peaked at $410K in Q1 2024. 890 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

C.M. Bidwell & Associates reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
C.M. Bidwell & Associates sold 2,946 DexCom shares in Q3 2024, an estimated $334K.
C.M. Bidwell & Associates first reported a position in DexCom in Q1 2015 and held it in 11 quarters.
C.M. Bidwell & Associates's DexCom position peaked at $410K in Q1 2024.
890 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2024, filed 13 Nov 2024.